Articles related to TARGETED THERAPIES

In a phase 3 trial comparing belzutifan to everolimus for advanced renal-cell carcinoma, belzutifan demonstrated a significant improvement in progression-free survival at 18 months (24.0% vs. 8.3%, P=0.002) and objective response rate (21.9% vs. 3.5%, P<0.001).

Sotorasib treatment in two patients with severe KRAS G12C-driven arteriovenous malformations resulted in rapid symptomatic improvement and sustained reduction in malformation volume over 24 months.

Researchers have identified insufficient activation of the aryl hydrocarbon receptor (AHR) pathway as a key driver in lupus pathogenesis, offering a new target for therapeutic intervention.

Careful management with endocrinology expertise is crucial when considering radioligand therapy for pheochromocytomas and paragangliomas to avoid potentially life-threatening catecholamine crises.

In a phase 3 trial, tisotumab vedotin showed a median overall survival of 11.5 months compared to 9.5 months with standard chemotherapy in patients with recurrent cervical cancer, representing a 30% reduction in the risk of death.

In a recent study, 95% of ITP patients treated with the novel anti-CD38 monoclonal antibody, CM313, achieved two consecutive platelet counts of at least 50×10^9 per liter within just eight weeks, highlighting the therapy’s efficacy and rapid action.